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Abstract
BACKGROUND: Decreased Natrium iodide symporter (NIS) expression levels or diminished NIS targeting thyroid 
cancer cells’ plasma membrane leads to radioiodine-refractory disease.
AIM: The aim of this study was to analyze the NIS expression in thyroid tumors.
MATERIALS AND METHODS: The samples were thyroid tissues of patients who underwent surgery for a thyroid 
tumor. The tissues were processed for NIS protein expressions by immunohistochemistry (IHC) and Western blot 
(WB). Graves’ disease samples were used as positive controls. The samples were incubated without the primary 
antibody, and they were used as negative controls for IHC examination. Na+/K+ ATPase was a plasma membrane 
protein marker in the WB procedure.
RESULTS: Twenty-nine samples were assessed for NIS protein. All of them showed the expression in the cytoplasm 
with intensity 1+ to 3+ with Allred score 3-8. Fourteen out of 29 cases (48.2%) showed NIS cytoplasm staining 
intensity ≥2+ consist of 10 papillary thyroid cancer (PTC), three follicular thyroid cancer, and one adenoma. 
Membrane staining was found in 2 samples of PTC (6.9%). Six samples (adenoma 1 sample, PTC 5 samples) 
showed NIS expression at membrane very weak (1+); they were considered as negative. NIS protein has several 
bands of ~ 80 kDa, ~ 62 kDa, and ~ 49 kDa.
CONCLUSION: NIS expression in thyroid cancer mostly expresses in the cytoplasm instead of the membrane. NIS 
will play a functional role in the membrane to bring iodine across the membrane against the concentration. It can be 
the main reason for the lack of response of radioiodine in some differentiated thyroid cancers.
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Introduction 
One of the most common endocrine neoplasms 
is thyroid cancer [1]. In most countries, thyroid cancer 
incidence rate has increased, and it does have a 
steady mortality rate [2], [3], [4], [5]. Thyroid cancer is 
the eleventh rank cause of deaths from cancer [6]. This 
cancer incidence is rapidly increasing in developed 
countries compared to developing countries in females 
and males [7]. The rising of advanced detection 
technologies and changing lifestyles in developed 
countries can be the reasons.
The follicular and parafollicular thyroid cells 
are two primary parenchymal cells of thyroid cancer 
origin. These can rise to be well-differentiated thyroid 
cancer (DTC) such as papillary and follicular types. 
Well-differentiated is the majority incidence of thyroid 
cancer, papillary (80%) and follicular (10%). Then, 
it is followed by poorly DTC, medullary (5-9%), and 
anaplastic (2%) [8]. DTC is associated with a good 
prognosis.
Radioiodine (131I) has been used for 
adjuvant therapy to manage well-DTC for more than 
60 years. Beta (β)-emitting of 131I is used to destroy 
remaining thyroid cells post-thyroidectomy included 
metastases [9], [10], [11], [12], [13]. It is relatively 
un-expensive and widely available. It increases up to 
80% of the 10-year survival rate and decreases the death 
number compared to patients who had not received 131I 
(3%: 12%) [14], [15]. On the other hand, some thyroid 
cancers and metastases showed low uptake of 131I 
compare to healthy thyroid tissues [16]. One-third of 
advanced DTC metastases show low avidity to iodine 
[8], [17], [18], [19]. Losing the ability to concentrate 
iodine can occur during the progression of the disease.
Iodine is transporting into follicular thyroid 
cells against the electrochemical gradient. In a normal 
condition, a gradient between a thyroid cell and an 
extracellular is 100:1 [20]. Natrium iodide symporter (NIS) 
is used for iodine to cross the cell membrane. It resides 
in the thyroid in the basolateral membrane of epithelial 
cells and transports two cations of sodium (Na+) and 
one anion of iodide (I-) into the cells. This process is 
facilitated by an enzyme Na+/K+ ATPase [21], [22], [23]. 
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Decreased NIS expression levels or diminished NIS 
targeting to thyroid cancer cells’ plasma membrane 
lead to radioiodine-refractory disease. The main 
reason for impaired of 131I uptake is defective of NIS 
expression  [15], [17], [23], [24]. This study aims to 
analyze the NIS expression in thyroid tumors. 
Materials and Methods
The samples were thyroid tissues of patients 
who underwent surgery for thyroid diseases during 
June to September 2017. Twenty-nine samples were 
classified as thyroid diseases, according to the World 
Health Organization recommendation by pathologists 
using hematoxylin and eosin staining [25]. The tissues 
were processed at the Pathology Anatomy Department 
of Faculty of Medicine Universitas Andalas. If the 
samples were not possible to process quickly, they were 
stored at –4°C. NIS protein expressions were analyzed 
by immunohistochemistry (IHC) and Western blot (WB) 
studies. Ethical approval was obtained from the Ethics 
Committee of Medical Faculty of Universitas Andalas # 
357/KEP/FK/2017.
IHC
Paraffin blocks cut into 4 mm slices and placed 
on microscope slides. These were then deparaffinized, 
rehydrated, and incubated with sodium iodide symporter 
antibody (FP5A, Thermo Scientific) at a 1:200 dilution 
for 60 min at room temperature. The slides were 
rinsed in phosphate-buffered saline and incubated in 
a Starr Trek Universal HRP Detection Kit for 15 min. 
Then, they were incubated using a diaminobenzidine 
detection kit. Graves’ disease samples were used as 
positive controls. The samples were incubated without 
the primary antibody, and they were used as negative 
controls.
All slides were evaluated by light microscopy. 
The level of NIS expression was analyzed by three 
pathologists. Samples were examined in tumor areas. 
The membrane expression was scored using a scale 
of 0 to 3+ according to HER2/neu staining criteria. A 
score of 0 if no stain at the membrane, score 1+ if the 
membrane was staining more than 10% cell population. 
A score of 0 or 1 was considered negative. Score 2+, if 
moderate staining >10% cell population and 3+ strong 
circumferential stainings >10% cell population. Score 2 
and 3 were considered a positive result [26]. Cytoplasmic 
staining refers to the Allred technique with criteria; 0 if 
no staining, 1+ weak staining at the majority of the field 
of view, 2+ moderate, and 3+ strong staining. Intensity 
value was reported as staining intensity majority in all 
fields of view. The proportion of positive cells is the 
percentage of all cell positive stain regardless of the 
level of intensity. It was reported in percentage. Allred 
score was summation between proportion and intensity 
with score 0–8 [27].
WB
Membrane protein was isolated from thyroid 
samples. The membrane protein (100 µg) was added 
to the sample buffer (NuPAGE LDS sample buffer 
×4, NuPAGE reducing Agent ×10, deionized water, 
Thermo Scientific) and heated for 10 min at 70°C. 
The protein was separated by SDS/PAGE (NuPAGE 
MOPS SDS buffer kit, Thermo Scientific), then 
transferred to a PVDF membrane (iBlot2 transfer 
stacks, Thermo Scientific) for 1.5 h. The blot stained 
to check protein on the membrane (SeeBlue Plus2, 
Thermo Scientific). Then, a blocking buffer was added 
to the membrane for 30 min to block nonspecific 
binding. It followed by incubating the membrane in 
monoclonal antibody sodium iodide symporter (FP5A, 
Thermo Scientific) 1:1000 at 4°C overnight. After 
three piles of washing, the membrane was incubated 
with secondary antibody 1:200 (goat anti-mouse IgG 
(H+L), Peroxidase Conjugate, Thermo Scientific) 
for 2 h at room temperature. Next, the membrane 
was covered with Horseradish peroxidase (1-step 
ultra tetramethylbenzidine-blotting solution). PVDF 
membrane was stripped and re-probed with Na+/K+ 
ATPase alpha antibody (M7-PB-E9, Thermo Scientific) 
as plasma membrane protein markers.
Statistical analysis
Experiments were performed in duplicate. Data 
and results are presented as the means ± standard 
deviations (SD). Kruskal–Wallis test and Mann–
Whitney were used for data analysis, and p < 0.05 was 
considered statistically significant.
Results
Twenty-nine samples were analyzed from 
patients who underwent thyroidectomy. Two males and 
27 females, and the mean age were 50.5 ± 10.5 years 
old. Papillary thyroid cancer (PTC) was 18 samples 
(62.1%), FTC three samples (10.3%), adenomas seven 
samples (24.2%), and Cyst one sample (3.4%) shown 
in Table 1.
IHC staining in thyroid tissues
Twenty-nine samples were assessed for 
NIS protein. All of them showed the expression in the 
cytoplasm with intensity 1+ to 3+ with Allred score 
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3–8. Fourteen out of 29 cases (48.2%) showed NIS 
cytoplasm staining intensity ≥2+, with Allred score 
6-8 (mean 6.85±0.53), consist of ten PTC, three FTC 
and one adenoma (Table 1, and Figure 1a-f, 2a-f). 
Figure 2: Cytoplasmic pattern of staining in thyroid cancer; weak 
(+) (a and b), moderate (++) (c and d),  and strong (+++) (e and f). 
There is no staining at the stromal cell and vascular. The majority of 
samples demonstrate Natrium iodide symporter expression intensity 
weak to moderate. Bar 100 μm
d
c
fb
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Fifteen samples (51.7%) the cytoplasm 
staining 1+, with Allred score 3–6 (mean 5.13±0.99), 
consist of eight PTC, six adenomas, one cyst. The 
protein expression was not significantly different (p 
= 0.77) between intensity of staining and WB results 
(Figure 3). Membrane staining was found in two (6.9%) 
samples of PTC samples (Figure 4a-c). Six samples 
(adenoma one sample, PTC five samples) showed NIS 
expression at membrane very weak (1+); they were 
considered as negative.
Figure 3: Natrium iodide symporter protein expressions based on 
thyroid disease types. The expression mostly in the cytoplasm in all 
types. Fourteen PTC samples expressed NIS in cytoplasm varying 
1+ to 2+ with bands ~80, ~62, and ~49 kDa. Membrane positive 
staining is found in 6.9% samples of PTC, which correlated with 
molecule weight ~80 kDa. FTC samples expressed NIS protein in 
the cytoplasm with intensity >1+ have a band ~80 kDa (above). 
Protein expression was not significantly different between IHC and 
WB. Percentage of NIS protein expression in cytoplasm expression 
with WB results in adenomas, PTC, and FTC, 60%,89%, 100%, 
respectively (below)
Table 1: Patients characteristics of thyroid tissues samples
S. No Age Gender Sample Histopathology ATP ~ 80 kDa NIS ~ 80 kDa Membrane staining Intensity Cytoplasm proportion Allred score
1 45 M 1P Adenoma + + - + 90 6
2 33 F 4P Cyst + - - + 90 6
3 47 F 5P PTC + + - + 80 6
4 35 M 6P PTC + - - ++ 80 7
5 42 F 7P PTC + 62 kDA - ++ 80 7
6 52 F 8P PTC + + - + 70 6
7 46 F 9P Adenoma + - - + 80 6
8 36 F 10P PTC + + - ++ 70 7
9 62 F 11P PTC + - - ++ 70 7
10 36 F 12P Adenoma + + + ++ 80 7
11 49 F 13P Adenoma + 49 kDa - + 50 5
12 58 F 14P PTC + + + ++ 90 7
13 48 F 15P FTC + + - ++ 60 6
14 52 F 16P PTC + + - + 70 6
15 74 F 17P PTC + 49 kDa - + 30 4
16 75 F 18P FTC + + - ++ 80 7
17 52 F 19P PTC + + - + 30 4
18 57 F 20P Adenoma NA NA - + 20 3
19 45 F 21P PTC + 62 kDa ++ + 60 5
20 55 F 22P PTC + - + + 50 5
21 36 F 23P PTC + + + ++ 50 6
22 54 F 25P PTC + 49 kDa + ++ 60 6
23 52 F 26P Adenoma NA NA - + 30 4
24 47 F 27P PTC NA NA - +++ 50 7
25 64 F 28P PTC + + ++ ++ 80 7
26 51 F 29P PTC + + - + 60 5
27 63 F 30P FTC + + - ++ 80 7
28 52 F 31P PTC + - + +++ 90 8
29 47 F 32P Adenoma + - - + 80 6
PTC: Papillary thyroid cancer, FTC: Follicular thyroid cancer, NIS: Natrium iodide symporter.
Figure 1: Cytoplasmic Natrium iodide symporter expression at follicle 
cell of adenoma goiter  show a weak intensity (+) (a and b), moderate 
(++) (c and d), and strong (+++) (e and f). No staining at stromal and 
vascular. Most of the samples show NIS cytoplasmic intensity weak 
to a moderate level. Bar 100 μm
d
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WB analysis in thyroid tissues
NIS protein was analyzed in 26 of 29 thyroid 
samples because only the large tumor size could 
proceed with WB analysis. NIS protein is detected with 
molecule weight ~80, ~62, and ~49 kDa. The samples 
consist of 17 PTC, three FTC, five adenomas, and one 
thyroid cyst (Table 1). Nineteen samples expressed NIS 
protein, three adenoma samples, and 13 PTC three 
FTC samples. They migrated with a molecular weight 
of ~ 80 kDa in 14 samples and four samples with a 
molecular weight of ~ 62 kDa. Two samples expressed 
NIS protein at the membrane, migrate with a molecular 
weight of ~ 80 kDa and ~ 62 kDa (Figure 5). There was 
no significantly different the protein expression between 
WB and IHC results, with p = 0.25.
Figure 5: Natrium iodide symporter expression blotting result in 
thyroid tissues; the major band is detected with molecular weight ~80 
kDa and several minor bands ~62, and ~49 kDa
Discussion
The classification samples were based on the 
histopathology examination. Seven of the samples were 
adenomas. All of them showed NIS protein expression 
in the cytoplasm in vary intensities (1+ to 3+). However, 
only one showed membrane expression 1+ with 
intensity in cytoplasm 2+, Allred scores 7, and the 
protein band ~80 kDa. The condition was also reported 
by other studies [28], [29], [30], [31]. The different 
staining intensity likely related to varying NIS protein 
expression in different thyroid sample types [31]. NIS 
protein is expressed in cytoplasm in all PTC and FTC, 
as shown in Table 1.
NIS protein major band with molecular weight 
~80 kDa, and several minor bands with molecular 
weight approximately 62 kDa and 49 kDa. This report 
in line with other studies [28], [29], [30], [31], [32]. The 
minor bands can be a degradation fragment. However, 
further studies are needed to elaborate on this issue. 
NIS protein-membrane was expressed in 6.9% samples 
of PTC, one with a molecular weight of ~80 kDa and 
another ~62 kDa.
NIS expression levels are generally 
reduced in malignant thyroid tissue relative to 
normal tissue [16], [33]. It may result from multiple 
mechanisms elicited by several signaling pathways 
involved in thyroid tumorigenesis included genetic 
alternations [31], [34], [35]. Understanding the 
molecular background for thyroid cancer can lead to 
developing agents blocking the inappropriately activated 
pathway in cancer cells as a novel treatment strategy. 
Furthermore, NIS expression appears to be modulated 
by post-transcriptional events. A study reported that 
NIS is differentially expressed according to the tumor’s 
genetic background [31]. However, the molecular 
mechanisms responsible for the downregulation of 
NIS in thyroid tumors remain poorly understood. On 
the other hand, NIS expression in the thyroid depends 
on inducing thyroid stimulation hormone (TSH), and 
low TSH levels affect 131I uptake. It is known that TSH 
stimulates radioiodine uptake by DTC cells [16], [18]. 
It may be another factor that leads to reduced NIS 
expression and iodide-concentrating capacity in the 
thyroid cells.
131I is generally effective for thyroid cancer. 
Two-thirds of thyroid cancer patients showed 131I 
uptake, and one-third of thyroid cancer is reported low 
or negative uptake of 131I, which has turned out to be 
ineffective [8]. Higher NIS expression is associated with 
higher uptake of 131I by thyroid cell [18], [34]. Thyroid 
cells that do not respond to radioiodine can be lost NIS 
expression [15], [17], [23], [24]. The availability of specific 
polyclonal and monoclonal anti-hNIS antibodies has 
allowed the investigation of NIS protein expression levels 
in various thyroid tissues. Around 70–80% of thyroid 
cancers that express NIS are still well-differentiated 
regardless of their stage [30], [36], [37]. It seems that 
cell differentiation in thyroid cancer may associate with 
the NIS expression and radioiodine accumulation [35], 
[36]. Undifferentiated thyroid cancer cells unable to 
concentrate 131I. It was assumed due to the absence of 
or low NIS expression [30], [38]. Impaired functional NIS 
can be the main reason for less response to a thyroid 
cancer cell to radioiodine. Some studies reported that 
NIS expresses mostly intracellular than at the plasma 
membrane [13], [18], [28], [29], [30], [31], [39].
A study reported that 131I therapy’s effectiveness 
does not solely depend on the amount of 131I, in which 
transport is facilitated by NIS [39]. A131I reduced breast 
Figure 4: Pattern of the staining at the membrane. Negative Natrium 
iodide symporter expression (a), weak membrane expression and 
intensity (1+) (b), moderate staining (2+) (c). No stain at stromal cell 
and vascular. Bar 100 µm
cba
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cancer cells (MCF7) proliferation in vitro, eventhough the 
cells did not express NIS protein [40], [41]. The condition 
can happen because the cell has its mechanism to the 
response of radiation [12], [13], [20], [42]. Another study 
reported that NIS expression might help characterize 
patients’ risk with inadequate therapy response [31], 
[43]. Further research related to biological tumor 
behavior to radioiodine exposure included retrospective 
studies in large number series, is still needed.
Conclusion
NIS expression in thyroid cancer mostly 
expresses in the cytoplasm than the membrane. It can 
be one of the reasons for the ineffective radioiodine in 
some DTCs. To achieve an appropriate 131I toxic effect 
without harming normal cells, translocation of NIS to the 
membrane may be one strategy that needs to consider 
tumor biology behavior. However, advanced studies of 
the NIS role in radioiodine transport are still needed.
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